Picking your GH secretagogue — Sermorelin, Ipamorelin, CJC, MK-677, Hexarelin

The clearest first step is to understand that there are two distinct mechanistic families here. They act on the same end goal — stimulating growth hormone release from the pituitary — but they achieve it via different receptors and through different upstream pathways. Choosing without understanding the families is like picking between two medications without knowing one is a beta-blocker and the other is a calcium channel antagonist. The outcome might look similar on paper. The mechanism and the trade-offs are not.

The first family is GHRH analogs. These work by mimicking growth hormone-releasing hormone — the natural hypothalamic signal that tells the pituitary to secrete GH. Sermorelin is the prototype: a 29-amino-acid synthetic version of the first 29 residues of the naturally occurring 44-amino-acid GHRH molecule, working through the GHRH receptor on somatotroph cells in the anterior pituitary. CJC-1295 without DAC is a modified GHRH analog with improved receptor binding affinity and a longer half-life than Sermorelin, but still cleared relatively quickly — designed to generate a GH pulse rather than a sustained elevation. CJC-1295 with DAC (Drug Affinity Complex) adds a technology that binds the peptide to albumin in the bloodstream, extending its half-life to approximately six to eight days and shifting it from a pulse-generating agent to one that produces a sustained elevation of GH and IGF-1. Tesamorelin is a GHRH analog with FDA approval specifically for HIV-associated lipodystrophy — it's the most clinically validated compound in this family and the only one with a formal approved indication, though it's researched more broadly for visceral fat reduction and some cognitive applications.

The second family is ghrelin mimetics — sometimes called growth hormone releasing peptides (GHRPs) or growth hormone secretagogues (GHS). These work through a different receptor: GHS-R1a, the ghrelin receptor. Ghrelin is the hunger hormone produced primarily in the stomach, and it independently stimulates GH release through a pathway that complements rather than overlaps with the GHRH pathway. This has an important practical implication: compounds from the two families work synergistically. Combining a GHRH analog with a ghrelin mimetic produces substantially more GH release than either alone — not just additively but synergistically — because they activate two separate receptor populations on the same pituitary cells. Ipamorelin is the cleanest and most selective ghrelin mimetic: it produces selective GH release with minimal effects on cortisol, prolactin, or ACTH. GHRP-2 is more potent than Ipamorelin but also raises cortisol and prolactin, which is relevant for long-term use. GHRP-6 adds significant appetite stimulation — via ghrelin receptor activity in the hypothalamus and gut — which some people find useful and others find disruptive. Hexarelin is the most potent GHRP but is associated with the fastest receptor desensitization, meaning continuous use leads to diminishing returns more rapidly than cleaner compounds. MK-677 (Ibutamoren) is an orally active non-peptide ghrelin mimetic — the only compound in this whole class that survives digestion and works as a pill rather than a subcutaneous injection — but its oral convenience comes with a specific trade-off profile: sustained GH and IGF-1 elevation rather than a pulsatile pattern, significant appetite stimulation, potential water retention and insulin resistance, and a half-life that means any side effects are not quickly resolved by stopping dosing.

Half-life matters more than it's often credited for. The natural pattern of GH secretion is pulsatile — large pulses during deep slow-wave sleep, smaller pulses throughout the day — and this pulsatility has functional significance beyond just the cumulative exposure. GH receptor signaling behaves differently in response to pulses versus continuous exposure, and somatostatin-mediated feedback is triggered more robustly by sustained elevated GH than by sharp pulses that return quickly to baseline. Short-acting compounds — Sermorelin, GHRP-2, Ipamorelin — produce pulses and return to baseline quickly, keeping the natural feedback loop largely intact. CJC-1295 without DAC occupies a middle position: longer half-life than Sermorelin but still generating a discrete pulse. CJC-1295 with DAC shifts toward continuous elevation, which produces larger sustained IGF-1 increases but moves away from physiological pulsatility. MK-677 is the most extreme case: continuous oral dosing creates sustained rather than pulsatile GH and IGF-1 elevation around the clock.

Selectivity is the other axis that doesn't get enough attention in these comparisons. Ipamorelin was specifically engineered to be selective for GH release — it was developed because earlier GHRPs (particularly GHRP-2 and GHRP-6) also raised cortisol, prolactin, and ACTH through off-target receptor activity. For most adults considering GH secretagogue support, raising cortisol chronically is the opposite of the goal: it counteracts the recovery, body composition, and sleep quality benefits you're trying to achieve. GHRP-2 has meaningful GH-releasing potency but the cortisol co-stimulation limits its utility in people who are already running high cortisol loads — which, candidly, is most adults seeking this kind of support. Hexarelin has the highest desensitization risk: studies in animals and early human data show that continuous Hexarelin use leads to rapid downregulation of GHS-R1a, requiring cycling protocols that add complexity without clear advantage over cleaner alternatives.

MK-677 deserves its own careful treatment because it's the compound people encounter most often in non-clinical contexts — it's oral, it's marketed as a research chemical, and it circulates in fitness communities at doses and in ways that aren't well-matched to its pharmacology. The appetite increase is not subtle: many users gain meaningful amounts of water weight in the first weeks, and the insulin resistance signal that appears in some human studies is real enough to matter for people with metabolic considerations. IGF-1 elevation from MK-677 at common doses is significant — which may be desirable for body composition and recovery goals, but also means IGF-1 monitoring is not optional if you're using it for an extended period. The convenience of not injecting is real. So is the trade-off profile.

The use case framing matters for making a good decision. If you're an adult with declining sleep quality, some evidence of reduced GH output, and interest in supporting slow-wave sleep depth and recovery without aggressive body composition targeting, the most appropriate starting point in most clinical peptide practices is Sermorelin alone or Ipamorelin alone — administered before sleep, clean mechanism, intact feedback loop, well-tolerated. If you're working toward more substantial effects on body composition, recovery speed, and lean mass maintenance — with clinical oversight and appropriate lab monitoring — an Ipamorelin plus CJC-1295 no-DAC stack is the combination most commonly used in clinical peptide programs precisely because the synergy between GHRH and GHRP pathways produces meaningfully greater GH output than either alone, while preserving selectivity and pulsatility. If visceral fat reduction is the primary target, Tesamorelin is the only compound in this entire family with an FDA approval in a related indication and published Phase III clinical data; the research on visceral fat specifically is more robust for Tesamorelin than for the other GHRH analogs. If you want oral convenience and the trade-offs of sustained GH elevation are acceptable within your clinical picture, MK-677 deserves a careful conversation with a prescribing provider who can review your metabolic labs, baseline IGF-1, and fasting insulin before and during use.

None of these compounds are FDA-approved for general adult GH support — that distinction belongs to recombinant HGH for specific diagnostic indications, not to secretagogues. Tesamorelin is the exception with its lipodystrophy approval. The rest exist as compounded medications in the United States, prescribed through providers who specialize in this area, outside the standard pharmaceutical approval pathway. The quality-of-evidence point matters: these compounds have real mechanistic research, real pharmacokinetics, and real clinical experience behind them — but the controlled trial data in healthy adults for general longevity, recovery, and body composition goals is not equivalent to a drug that has cleared Phase III. These are not equivalent standards of evidence, and good decision-making holds that honestly.

The monitoring question is not optional. IGF-1 is the primary biomarker — it's the downstream readout of GH stimulation, it's measurable in blood, and it's the number that tells you whether a secretagogue protocol is producing GH output in a range that makes sense for your age and goals. Using any compound in this class without periodic IGF-1 measurement is flying blind. Fasting glucose and fasting insulin matter if you're using compounds with potential metabolic effects (MK-677 particularly). Baseline labs before starting any protocol, and periodic reassessment during, is not bureaucratic caution. It's the difference between knowing what you're doing and hoping it's working.

The decision tree collapses to a simpler question once you understand the landscape: what's your primary goal, what's your tolerance for complexity and injection frequency, and what does your metabolic baseline look like? Those three inputs, combined with a prescribing provider who can review your actual clinical picture, determine which compound or combination belongs in your protocol. The answer isn't the same for every person. The framework for finding it is.